The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
Abstract
Potential conflict of interest: Listed at the end of the article for all authors. These recommendations have been approved by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Potential conflict of interest: Listed at the end of the article for all authors. All AASLD Practice Guidelines are updated annually. If you are viewing a Practice Guideline that is more than 12 months old, please visit www.aasld.org for an update in the material. Preamble The pace of hepatitis C virus (HCV) drug development in recent years has accelerated dramatically. For patients to benefit from these impressive advances, practitioners need access to the most up‐to‐date data and to advice from experienced experts. Such information and advice can be difficult to access readily given the diverse sources from which information is available and the sometimes lengthy time needed for publication of original articles and scholarly perspectives. Traditional practice guidelines for more established areas of medicine and care often take years to develop and bring to publication. In the new era in hepatitis C treatment, such a process would not be nimble or timely enough to address the needs of patients with HCV infection, practitioners caring for these patients, or payers approving therapies for use. A living document made available in a web‐based system, such as that used by the US Department of Health and Human Services for human immunodeficiency virus (HIV) treatment recommendations (http://aidsinfo.nih.gov/guidelines), was selected as the best model to provide timely recommendations for hepatitis C management. In 2013, the two major membership societies supporting liver and infectious disease specialists (American Association for the Study of Liver Diseases [AASLD] and Infectious Diseases Society of America [IDSA]) joined forces to develop guidance for the management of hepatitis C in this rapidly moving field. The International Antiviral Society‐USA, which has experience in developing treatment guidelines in HIV disease, was invited to join the effort as a collaborating partner responsible for managing the panel and the guidance development process. The goal of the hepatitis C guidance is to provide up‐to‐date recommendations for HCV care practitioners on the optimal screening, management, and treatment for adults with HCV infection in the United States, using a rigorous review process to evaluate the best available evidence. This review provides a condensed summary of recommendations from the guidance. The complete guidance, which is updated regularly, is available at www.hcvguidelines.org. Process This was conceived to be a living document that would reside online and undergo real‐time revisions as the field evolved. To lead the process, two cochairs selected by the governing boards of each founding society were joined by a fifth cochair representing the International Antiviral Society‐USA. These cochairs selected 10 panel members from each society. The panel members were chosen to represent expertise in the diagnosis, management, treatment, research, and patient care from the fields of hepatology and infectious diseases. At least 51% of the panelists could have no substantive industry support other than research advisory boards, data safety monitoring boards, or research funding that went to the member's employer. The panel first convened in person in October 2013. Panel members were divided into teams to review available data and to propose preliminary guidance in three areas: (1) testing and linkage to care, (2) initial treatment of HCV infection, and (3) retreatment of patients in whom prior HCV treatment had failed. The treatment section teams also reviewed data for special considerations in patients with hepatitis C, including those with HCV/HIV coinfection, with decompensated cirrhosis, and who had undergone liver transplantation. The teams and cochairs met regularly by conference call. All panel members reviewed and approved the final recommendations. Each society's governing board peer‐reviewed the final recommendations. The first version of the guidance was uploaded (www.hcvguidelines.org) on January 29, 2014. By September 2014, three additional sections were developed: (1) treatment of acute HCV infection, (2) monitoring during and after therapy, and (3) when and whom to treat. In October 2014, the panel reconvened in person to update recommendations to consider data on pending new treatments. The updated recommendations (and appropriate revisions of all current guidance) were uploaded on December 20, 2014. This report was prepared on May 20, 2015. Funding for the guidance itself was provided by the AASLD and the IDSA. No industry funding was solicited or accepted. The Centers for Disease Control and Prevention (CDC) provided separate funding for identifying and reviewing data pertaining to testing and linkage to care. Collecting, Evaluating, and Rating the Evidence The
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009) · Hepatology · doi:10.1002/hep.22759 · Cited by 2,973
Hadziyannis, S. J., Sette, H., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Bernstein, D., Rizzetto, M., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00010 · Cited by 2,836
Sampling Variability of Liver Fibrosis in Chronic Hepatitis C
Bedossa, P., Dargère, D., & Paradis, V. (2003) · Hepatology · doi:10.1016/j.hep.2003.09.022 · Cited by 2,376
Surveillance for waterborne-disease outbreaks--United States, 1993-1994.
Kramer, M. H., Herwaldt, B. L., Craun, G. F., Calderon, R. L., & Juranek, D. D. (1996) · PubMed · Cited by 2,059
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S. C., Schultz, M., Davis, M. N., Kayali, Z., Reddy, K. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214853 · Cited by 1,788
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis
Garcia-Tsao, G., Sanyal, A. J., Grace, N. D., & Carey, W. (2007) · Hepatology · doi:10.1002/hep.21907 · Cited by 1,722
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M., Romero-Gomez, M., Zarski, J.-P., Agarwal, K., Buggisch, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402454 · Cited by 1,705
van der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H., Dufour, J.-F., Lammert, F., Duarte-Rojo, A., Heathcote, E. J., Manns, M. P., Kuske, L., et al. (2012) · JAMA · doi:10.1001/jama.2012.144878 · Cited by 1,510
Ziol, M., Handra-Luca, A., Kettaneh, A., Christidis, C., Mal, F., Kazemi, F., de Lédinghen, V., Marcellin, P., Dhumeaux, D., Trinchet, J.-C., et al. (2005) · Hepatology · doi:10.1002/hep.20506 · Cited by 1,470
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Afdhal, N., Reddy, K. R., Nelson, D. R., Lawitz, E., Gordon, S. C., Schiff, E., Nahass, R., Ghalib, R., Gitlin, N., Herring, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316366 · Cited by 1,307
Torriani, F. J., Rodriguez-Torres, M., Rockstroh, J. K., Lissen, E., Gonzalez-García, J., Lazzarin, A., Carosi, G., Sasadeusz, J., Katlama, C., Montaner, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040842 · Cited by 1,233
(1998) · PsycEXTRA Dataset · doi:10.1037/e547602006-001 · Cited by 1,213
Poynard, T., McHutchison, J., Manns, M., Trepo, C., Lindsay, K., Goodman, Z., Ling, M., & Albrecht, J. (2002) · Gastroenterology · doi:10.1053/gast.2002.33023 · Cited by 1,146
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kowdley, K. V., Gordon, S. C., Reddy, K. R., Rossaro, L., Bernstein, D. E., Lawitz, E., Shiffman, M. L., Schiff, E., Ghalib, R., Ryan, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402355 · Cited by 1,130
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Jacobson, I. M., Gordon, S. C., Kowdley, K. V., Yoshida, E. M., Rodriguez-Torres, M., Sulkowski, M. S., Shiffman, M. L., Lawitz, E., Everson, G., Bennett, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214854 · Cited by 1,090
The Natural History of Hepatitis C Virus Infection: Host, Viral, and Environmental Factors
Thomas, D. L., Astemborski, J., Rai, R. M., Anania, F. A., Schaeffer, M., Galai, N., Nolt, K., Nelson, K. E., Strathdee, S. A., Johnson, L., et al. (2000) · JAMA · doi:10.1001/jama.284.4.450 · Cited by 1,073
Smith, B. D., Morgan, R. L., Beckett, G. A., Falck-Ytter, Y. T., Holtzman, D. J., Teo, C., Jewett, A., Baack, B. N., Rein, D. B., Patel, N., et al. (2012) · PubMed · Cited by 991
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Feld, J. J., Kowdley, K. V., Coakley, E., Sigal, S., Nelson, D. R., Crawford, D., Weiland, O., Aguilar, H., Xiong, J., Pilot-Matias, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315722 · Cited by 903
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Poordad, F., Hezode, C., Trinh, R., Kowdley, K. V., Zeuzem, S., Agarwal, K., Shiffman, M. L., Wedemeyer, H., Berg, T., Yoshida, E. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402869 · Cited by 874
Aberg, J. A., Kaplan, J. E., Libman, H., Emmanuel, P., Anderson, J. R., Stone, V. E., Oleske, J. M., Currier, J. S., & Gallant, J. E. (2009) · Clinical Infectious Diseases · doi:10.1086/605292 · Cited by 837
Morgan, R. L., Baack, B., Smith, B. D., Yartel, A., Pitasi, M., & Falck-Ytter, Y. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-5-201303050-00005 · Cited by 829
Lawitz, E., Sulkowski, M. S., Ghalib, R., Rodriguez-Torres, M., Younossi, Z. M., Corregidor, A., DeJesus, E., Pearlman, B., Rabinovitz, M., Gitlin, N., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61036-9 · Cited by 818
Weinbaum, C. M., Mast, E. E., & Ward, J. W. (2009) · Hepatology · doi:10.1002/hep.22882 · Cited by 815
Hermine, O., Lefrère, F., Bronowicki, J.-P., Mariette, X., Jondeau, K., Eclache-Saudreau, V., Delmas, B., Valensi, F., Cacoub, P., Brechot, C., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013376 · Cited by 807
Denniston, M. M., Jiles, R. B., Drobeniuc, J., Klevens, R. M., Ward, J. W., McQuillan, G. M., & Holmberg, S. D. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1133 · Cited by 724
ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Ferenci, P., Bernstein, D., Lalezari, J., Cohen, D., Luo, Y., Cooper, C., Tam, E., Marinho, R. T., Tsai, N., Nyberg, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402338 · Cited by 693
Fibrosis in Chronic Hepatitis C Correlates Significantly With Body Mass Index and Steatosis
Hourigan, L. F., Macdonald, G. A., Purdie, D., Whitehall, V. H., Shorthouse, C., Clouston, A., & Powell, E. E. (1999) · Hepatology · doi:10.1002/hep.510290401 · Cited by 674
Mohaghegh, H. (2014) · Journal of Liver · doi:10.4172/2167-0889.1000147 · Cited by 609
Veldt, B. J., Heathcote, E. J., Wedemeyer, H., Reichen, J., Hofmann, W. P., Zeuzem, S., Manns, M. P., Hansen, B. E., Schalm, S. W., & Janssen, H. L. A. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-10-200711200-00003 · Cited by 602
A Meta-Analysis of Randomized Trials for the Treatment of Nonalcoholic Fatty Liver Disease
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2010) · Hepatology · doi:10.1002/hep.23623 · Cited by 564
Lawitz, E., Poordad, F. F., Pang, P. S., Hyland, R. H., Ding, X., Mo, H., Symonds, W. T., McHutchison, J. G., & Membreno, F. E. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62121-2 · Cited by 547
Gerlach, J. T., Diepolder, H. M., Zachoval, R., Gruener, N. H., Jung, M.-C., Ulsenheimer, A., Schraut, W. W., Schirren, C. A., Waechtler, M., Backmund, M., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00668-1 · Cited by 524
Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Zeuzem, S., Jacobson, I. M., Baykal, T., Marinho, R. T., Poordad, F., Bourlière, M., Sulkowski, M. S., Wedemeyer, H., Tam, E., Desmond, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401561 · Cited by 517
Aberg, J. A., Gallant, J. E., Ghanem, K. G., Emmanuel, P., Zingman, B. S., & Horberg, M. A. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit665 · Cited by 496
A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C
Backus, L. I., Boothroyd, D. B., Phillips, B. R., Belperio, P., Halloran, J., & Mole, L. A. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.004 · Cited by 481
Outcome of Sustained Virological Responders With Histologically Advanced Chronic Hepatitis C†,‡,§,¶
Morgan, T. R., Ghany, M. G., Kim, H.-Y., Snow, K. K., Shiffman, M. L., De Santo, J. L., Lee, W. M., Di Bisceglie, A. M., Bonkovsky, H. L., Dienstag, J. L., et al. (2010) · Hepatology · doi:10.1002/hep.23744 · Cited by 479
Moyer, V. A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-5-201309030-00672 · Cited by 475
Persistence of Viremia and the Importance of Long–Term Follow–Up After Acute Hepatitis C Infection
Villano, S. A., Vlahov, D., Nelson, K. E., Cohn, S., & Thomas, D. L. (1999) · Hepatology · doi:10.1002/hep.510290311 · Cited by 475
Shiffman, R. N., Shekelle, P., Overhage, J. M., Slutsky, J., Grimshaw, J., & Deshpande, A. M. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-6-200309160-00013 · Cited by 451
Impact of alcohol on the histological and clinical progression of Hepatitis C infection
Wiley, T. E., McCarthy, M., Breidi, L., McCarthy, M., & Layden, T. J. (1998) · Hepatology · doi:10.1002/hep.510280330 · Cited by 436
Thein, H.-H., Yi, Q., Dore, G. J., & Krahn, M. D. (2008) · AIDS · doi:10.1097/qad.0b013e32830e6d51 · Cited by 409
George, S. L., Bacon, B. R., Brunt, E. M., Mihindukulasuriya, K. L., Hoffmann, J., & Di Bisceglie, A. M. (2009) · Hepatology · doi:10.1002/hep.22694 · Cited by 399
Screening for HIV: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-1-201307020-00645 · Cited by 393
Grebely, J., Page, K., Sacks-Davis, R., van der Loeff, M. S., Rice, T. M., Bruneau, J., Morris, M. D., Hajarizadeh, B., Amin, J., Cox, A. L., et al. (2014) · Hepatology · doi:10.1002/hep.26639 · Cited by 388
Denniston, M. M., Klevens, M. R., McQuillan, G. M., & Jiles, R. B. (2012) · Hepatology · doi:10.1002/hep.25556 · Cited by 378
Characteristics of patients with dual infection by hepatitis B and C viruses
Zarski, J.-P., Bohn, B., Bastie, A., Pawlotsky, J.-M., Baud, M., Bost-Bezeaux, F., van Nhieu, J. T., Seigneurin, J.-M., Buffet, C., & Dhumeaux, D. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80198-0 · Cited by 374
Andreone, P., Colombo, M. G., Enejosa, J. V., Koksal, I., Ferenci, P., Maieron, A., Müllhaupt, B., Horsmans, Y., Weiland, O., Reesink, H. W., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.045 · Cited by 365
Singal, A. G., Volk, M. L., Jensen, D., Di Bisceglie, A. M., & Schoenfeld, P. S. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.11.018 · Cited by 362
Curry, M. P., Forns, X., Chung, R. T., Terrault, N. A., Brown, R., Fenkel, J. M., Gordon, F., O’Leary, J., Kuo, A., Schiano, T., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.09.023 · Cited by 334
Swain, M. G., Lai, M., Shiffman, M. L., Cooksley, W. G. E., Zeuzem, S., Dieterich, D. T., Abergel, A., Pessôa, M. G., Lin, A., Tietz, A., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.07.009 · Cited by 328
Testing for HCV Infection: An Update of Guidance for Clinicians and Laboratorians
Getchell, J. P., Wroblewski, K., DeMaria, A., et al. (2013) · PubMed Central · Cited by 325
Corrao, G., & Aricò, S. (1998) · Hepatology · doi:10.1002/hep.510270404 · Cited by 324
Alter, M. J., Kuhnert, W. L., & Finelli, L. (2003) · PubMed · Cited by 320
Use and interpretation of virological tests for hepatitis C
Pawlotsky, J.-M. (2002) · Hepatology · doi:10.1053/jhep.2002.36815 · Cited by 320
Hepatitis C in the United States
Holmberg, S. D., Spradling, P. R., Moorman, A. C., & Denniston, M. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1302973 · Cited by 317
Sulkowski, M. S., Eron, J. J., Wyles, D., Trinh, R., Lalezari, J., Wang, C., Slim, J., Bhatti, L., Gathe, J., Ruane, P. J., et al. (2015) · JAMA · doi:10.1001/jama.2015.1328 · Cited by 303
Hézode, C., Asselah, T., Reddy, K. R., Hassanein, T., Berenguer, M., Fleischer-Stepniewska, K., Marcellin, P., Hall, C., Schnell, G., Pilot-Matias, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60159-3 · Cited by 259
Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
Sulkowski, M. S., Naggie, S., Lalezari, J., Fessel, W. J., Mounzer, K., Shuhart, M., Luetkemeyer, A. F., Asmuth, D., Gaggar, A., Ni, L., et al. (2014) · JAMA · doi:10.1001/jama.2014.7734 · Cited by 254
Bellentani, S., Pozzato, G., Saccoccio, G., Crovatto, M., Crocè, L. S., Mazzoran, L., Masutti, F., Cristianini, G., & Tiribelli, C. (1999) · Gut · doi:10.1136/gut.44.6.874 · Cited by 246
Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic.
Wandeler, G., Gsponer, T., Bregenzer, A., Günthard, H. F., Clerc, O., Calmy, A., Stöckle, M., Bernasconi, E., Furrer, H., & Rauch, A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis694 · Cited by 241
Contribution of obesity to hepatitis C-related fibrosis progression
Ortiz, V (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04352-6 · Cited by 233
Prospective Evaluation of Community‐Acquired Acute‐Phase Hepatitis C Virus Infection
Cox, A. L., Netski, D. M., Mosbruger, T., Sherman, S. G., Strathdee, S., Ompad, D., Vlahov, D., Chien, D., Shyamala, V., Ray, S. C., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/428578 · Cited by 231
Effect of Human Immunodeficiency Virus on Hepatitis C Virus Infection among Injecting Drug Users
Thomas, D. L., Shih, J. W., Alter, H. J., Vlahov, D., Cohn, S., Hoover, D. R., Cheung, L., & Nelson, K. E. (1996) · Journal of Infectious Diseases · doi:10.1093/infdis/174.4.690 · Cited by 226
Castéra, L., Sebastiani, G., Le Bail, B., de Lédinghen, V., Couzigou, P., & Alberti, A. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.11.008 · Cited by 214
Everhart, J. E., Wright, E. C., Goodman, Z. D., Dienstag, J. L., Hoefs, J. C., Kleiner, D. E., Ghany, M. G., Mills, S. A., Nash, R. S., Govindarajan, S., et al. (2010) · Hepatology · doi:10.1002/hep.23315 · Cited by 208
Osinusi, A., Townsend, K., Kohli, A., Nelson, A., Seamon, C., Meissner, E. G., Bon, D., Silk, R., Gross, C., Price, A., et al. (2015) · JAMA · doi:10.1001/jama.2015.1373 · Cited by 203
Sulkowski, M. S., Sherman, K. E., Dieterich, D. T., Bsharat, M., Mahnke, L., Rockstroh, J. K., Gharakhanian, S., McCallister, S., Henshaw, J., Girard, P.-M., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-2-201307160-00654 · Cited by 201
Harris, D. R., Gonin, R., Alter, H. J., Wright, E. C., Buskell, Z. J., Hollinger, F. B., Seeff, L. B., & for the National Heart, L. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00012 · Cited by 194
Barriers to the treatment of hepatitis C: Patient, provider, and system factors
Morrill, J. A., Shrestha, M., & Grant, R. W. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.0161.x · Cited by 180
SAFE biopsy: A validated method for large‐scale staging of liver fibrosis in chronic hepatitis C†
Sebastiani, G., Halfon, P., Castera, L., Pol, S., Thomas, D. L., Mangia, A., Marco, V. D., Pirisi, M., Voiculescu, M., Guido, M., et al. (2009) · Hepatology · doi:10.1002/hep.22859 · Cited by 180
(2008) · Kidney International · doi:10.1038/ki.2008.83 · Cited by 176
Incidence and Transmission Patterns of Acute Hepatitis C in the United States, 1982-2006
Williams, I. T., Bell, B. P., Kuhnert, W., & Alter, M. J. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.511 · Cited by 175
End-stage liver disease in persons with hemophilia and transfusion-associated infections.
Goedert, J. J., Eyster, M. E., Lederman, M. M., Mandalaki, T., de Moerloose, P., White, G., Angiolillo, A. L., Luban, N. L. C., Sherman, K. E., Manco‐Johnson, M. J., et al. (2002) · PubMed · Cited by 171
Short-term interferon-alfa therapy for acute hepatitis C: A randomized controlled trial
Nomura, H., Sou, S., Tanimoto, H., Nagahama, T., Kimura, Y., Hayashi, J., Ishibashi, H., & Kashiwagi, S. (2004) · Hepatology · doi:10.1002/hep.20196 · Cited by 168
Ruane, P. J., Ain, D., Stryker, R., Meshrekey, R., Soliman, M., Wolfe, P. R., Riad, J., Mikhail, S., Kersey, K., Jiang, D., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.044 · Cited by 167
Dienstag, J. L., Ghany, M. G., Morgan, T. R., Di Bisceglie, A. M., Bonkovsky, H. L., Kim, H.-Y., Seeff, L. B., Szabo, G., Wright, E. C., Sterling, R. K., et al. (2011) · Hepatology · doi:10.1002/hep.24370 · Cited by 165
Raghuraman, S., Park, H., Osburn, W. O., Winkelstein, E. R., Edlin, B. R., & Rehermann, B. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir835 · Cited by 160
Safdar, K., & Schiff, E. R. (2004) · Seminars in Liver Disease · doi:10.1055/s-2004-832942 · Cited by 147
Witt, M. D., Seaberg, E. C., Darilay, A. T., Young, S., Badri, S. M., Rinaldo, C. R., Jacobson, L. P., Detels, R., & Thio, C. L. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit197 · Cited by 132
Comparison of Eight Diagnostic Algorithms for Liver Fibrosis in Hepatitis C
Boursier, J., de Lédinghen, V., Zarski, J., Fouchard‐Hubert, I., Gallois, Y., Oberti, F., & Calès, P. (2011) · Hepatology · doi:10.1002/hep.24654 · Cited by 126
Lee, S. R., Kardos, K. W., Schiff, E. R., Berne, C. A., Mounzer, K., Banks, A. T., Tatum, H. A., Friel, T. J., DeMicco, M. P., Lee, W. M., et al. (2010) · Journal of Virological Methods · doi:10.1016/j.jviromet.2010.12.009 · Cited by 111
Younossi, Z. M., Stepanova, M., Henry, L. L., Gane, E. J., Jacobson, I. M., Lawitz, E., Nelson, D. R., Gerber, L. H., Nader, F., & Hunt, S. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.11.032 · Cited by 93
Neary, M. P., Cort, S., Bayliss, M. S., & Ware, J. E. (1999) · PubMed · Cited by 80
Pockros, P. J., Reddy, K. R., Mantry, P., et al. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)30147-1 · Cited by 74
Sustained virological response: A milestone in the treatment of chronic hepatitis C
Morisco, F., Granata, R., Stroffolini, T., Guarino, M., Donnarumma, L., Gaeta, L., Loperto, I., Gentile, I., Auriemma, F., & Caporaso, N. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i18.2793 · Cited by 70
Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection
Chou, R., & Wasson, N. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-5-201309030-00021 · Cited by 69
Landau, D. A., Scerra, S., Sène, D., Resche‐Rigon, M., Saadoun, D., & Cacoub, P. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.090790 · Cited by 69
Linas, B. P., Wong, A. Y., Schackman, B. R., Kim, A. Y., & Freedberg, K. A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis382 · Cited by 61
Lawitz, E., Matusow, G., DeJesus, E., et al. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)30158-6 · Cited by 59
Fabrizi, F., Dixit, V., & Messa, P. (2013) · Journal of Medical Virology · doi:10.1002/jmv.23562 · Cited by 55
Mahajan, R., Liu, S. J., Klevens, R. M., & Holmberg, S. D. (2013) · American Journal of Public Health · doi:10.2105/ajph.2013.301211 · Cited by 27
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Ultrasound Elastography: Review of Techniques and Clinical Applications
Sigrist, R. M. S., Liau, J., Kaffas, A. E., Chammas, M. C., & Willmann, J. K. (2017) · Theranostics · doi:10.7150/thno.18650 · Cited by 1,877
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.006 · Cited by 1,875
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Karlas, T., Petroff, D., Sasso, M., Fan, J.-G., Mi, Y.-Q., de Lédinghen, V., Kumar, M., Lupsor-Platon, M., Han, K.-H., Cardoso, A. C., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.022 · Cited by 1,275
Metadata
- Authors
- Panel, A. H. G.
- Venue
- Hepatology
- Published
- 2015-08-04
- Volume
- 62
- Issue
- 3
- Pages
- 932-954
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W971519378
- Cited by
- 1,382
- References
- 94
- FWCI
- 154.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.